2-(2-OXo-2,3-dihydro-1h-imidazo[1,2-a]benzimidazol-3-yl)-n-propylacetamide

Catalog No. :
ACLLCW971
CAS No. :
1428139-00-7
Molecular Formula :
C14H16N4O2
Molecular Weight :
272.31

IUPAC Name:2-(2-oxo-2,3-dihydro-1H-benzo[d]imidazo[1,2-a]imidazol-3-yl)-N-propylacetamide

2-(2-OXo-2,3-dihydro-1h-imidazo[1,2-a]benzimidazol-3-yl)-n-propylacetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$258.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(2-OXo-2,3-dihydro-1h-imidazo[1,2-a]benzimidazol-3-yl)-n-propylacetamide
IUPAC Name2-(2-oxo-2,3-dihydro-1H-benzo[d]imidazo[1,2-a]imidazol-3-yl)-N-propylacetamide
MDL No.MFCD27936963
Molecular FormulaC14H16N4O2
Molecular Weight272.31
SMILESCCCNC(CC1N2C(NC1=O)=NC3=C2C=CC=C3)=O
InChI KeyORPAAUUSEGXBST-UHFFFAOYSA-N
Synonym2-(2-oxo-2,3-dihydro-1H-imidazo[1,2-a]benzimidazol-3-yl)-N-propylacetamide;1H-Imidazo[1,2-a]benzimidazole-3-acetamide, 2,3-dihydro-2-oxo-N-propyl-
CAS No.1428139-00-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACLLCW971 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGTAQ598 route compound structure diagram
    ACGTAQ598556-53-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLLCW971 route product structure diagram
    ACLLCW9711428139-00-7
Inquiry

2. ACLLCW971 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGTAQ598 route compound structure diagram
    ACGTAQ598556-53-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLLCW971 route product structure diagram
    ACLLCW9711428139-00-7
Inquiry

Comments (0)